Yinuo Si: Zhangjiang biopharmaceutical base intends to acquire 4.2294 million shares.

Yinuos announcement, Shanghai Zhangjiang Biomedical Development Co., Ltd. plans to acquire 4.2294 million shares of the company, accounting for 3.00% of the total share capital. The transferee is an institutional investor with corresponding pricing and risk-bearing capabilities, and shall not transfer the shares within 6 months after the acquisition. The shares held by the transferor have been released from restrictions and the ownership is clear.